RAS Variant Signalling

Overview

Journal Biochem Soc Trans

Specialty Biochemistry

Date 2018 Oct 6

PMID 30287508

Citations 47

Authors

Stephanie P Mo

Judy M Coulson

Ian A Prior

Affiliations

Soon will be listed here.

Abstract

RAS proteins are small GTPases that regulate signalling networks that control cellular proliferation and survival. They are frequently mutated in cancer and a commonly occurring group of developmental disorders called RASopathies. We discuss recent findings describing how RAS isoforms and different activating mutations differentially contribute to normal and disease-associated biology and the mechanisms that have been proposed to underpin this.

Citing Articles

KRAS Mutation Status in Relation to Clinicopathological Characteristics of Romanian Colorectal Cancer Patients.

Avadanei E, Caruntu I, Nuca I, Balan R, Lozneanu L, Giusca S Curr Issues Mol Biol. 2025; 47(2).

PMID: 39996841 PMC: 11854687. DOI: 10.3390/cimb47020120.

Advances and Challenges in RAS Signaling Targeted Therapy in Leukemia.

Chen Y, Yin Z, Westover K, Zhou Z, Shu L Mol Cancer Ther. 2024; 24(1):33-46.

PMID: 39404173 PMC: 11694067. DOI: 10.1158/1535-7163.MCT-24-0504.

KRAS Mutation Subtypes and Their Association with Other Driver Mutations in Oncogenic Pathways.

Mondal K, Posa M, Shenoy R, Roychoudhury S Cells. 2024; 13(14.

PMID: 39056802 PMC: 11274496. DOI: 10.3390/cells13141221.

The rapidly changing field of predictive biomarkers of non-small cell lung cancer.

Toth L, Mokanszki A, Mehes G Pathol Oncol Res. 2024; 30:1611733.

PMID: 38953007 PMC: 11215025. DOI: 10.3389/pore.2024.1611733.

Precision medicine for pancreatic cancer: characterizing the clinicogenomic landscape and outcomes of KRAS G12C-mutated disease.

Keane F, Chou J, Walch H, Schoenfeld J, Singhal A, Cowzer D J Natl Cancer Inst. 2024; 116(9):1429-1438.

PMID: 38702822 PMC: 11378314. DOI: 10.1093/jnci/djae095.

References

Schubbert S, Zenker M, Rowe S, Boll S, Klein C, Bollag G . Germline KRAS mutations cause Noonan syndrome. Nat Genet. 2006; 38(3):331-6. DOI: 10.1038/ng1748. View

Vizan P, Boros L, Figueras A, Capella G, Mangues R, Bassilian S . K-ras codon-specific mutations produce distinctive metabolic phenotypes in NIH3T3 mice [corrected] fibroblasts. Cancer Res. 2005; 65(13):5512-5. DOI: 10.1158/0008-5472.CAN-05-0074. View

To M, Wong C, Karnezis A, Del Rosario R, Di Lauro R, Balmain A . Kras regulatory elements and exon 4A determine mutation specificity in lung cancer. Nat Genet. 2008; 40(10):1240-4. PMC: 2654781. DOI: 10.1038/ng.211. View

Stolze B, Reinhart S, Bulllinger L, Frohling S, Scholl C . Comparative analysis of KRAS codon 12, 13, 18, 61, and 117 mutations using human MCF10A isogenic cell lines. Sci Rep. 2015; 5:8535. PMC: 4336936. DOI: 10.1038/srep08535. View

Forbes S, Bindal N, Bamford S, Cole C, Kok C, Beare D . COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res. 2010; 39(Database issue):D945-50. PMC: 3013785. DOI: 10.1093/nar/gkq929. View

Winters I, Chiou S, Paulk N, McFarland C, Lalgudi P, Ma R . Multiplexed in vivo homology-directed repair and tumor barcoding enables parallel quantification of Kras variant oncogenicity. Nat Commun. 2017; 8(1):2053. PMC: 5727199. DOI: 10.1038/s41467-017-01519-y. View

Willumsen B, Christensen A, Hubbert N, Papageorge A, Lowy D . The p21 ras C-terminus is required for transformation and membrane association. Nature. 1984; 310(5978):583-6. DOI: 10.1038/310583a0. View

Hobbs G, Der C, Rossman K . RAS isoforms and mutations in cancer at a glance. J Cell Sci. 2016; 129(7):1287-92. PMC: 4869631. DOI: 10.1242/jcs.182873. View

Mageean C, Griffiths J, Smith D, Clague M, Prior I . Absolute Quantification of Endogenous Ras Isoform Abundance. PLoS One. 2015; 10(11):e0142674. PMC: 4641634. DOI: 10.1371/journal.pone.0142674. View

10.

Prakash P, Zhou Y, Liang H, Hancock J, Gorfe A . Oncogenic K-Ras Binds to an Anionic Membrane in Two Distinct Orientations: A Molecular Dynamics Analysis. Biophys J. 2016; 110(5):1125-38. PMC: 4788746. DOI: 10.1016/j.bpj.2016.01.019. View

11.

Omerovic J, Hammond D, Clague M, PRIOR I . Ras isoform abundance and signalling in human cancer cell lines. Oncogene. 2007; 27(19):2754-62. PMC: 2557550. DOI: 10.1038/sj.onc.1210925. View

12.

Harding A, Hancock J . Ras nanoclusters: combining digital and analog signaling. Cell Cycle. 2008; 7(2):127-34. PMC: 2782570. DOI: 10.4161/cc.7.2.5237. View

13.

Hunter J, Manandhar A, Carrasco M, Gurbani D, Gondi S, Westover K . Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations. Mol Cancer Res. 2015; 13(9):1325-35. DOI: 10.1158/1541-7786.MCR-15-0203. View

14.

Aoki Y, Niihori T, Inoue S, Matsubara Y . Recent advances in RASopathies. J Hum Genet. 2015; 61(1):33-9. DOI: 10.1038/jhg.2015.114. View

15.

Walsh A, Bar-Sagi D . Differential activation of the Rac pathway by Ha-Ras and K-Ras. J Biol Chem. 2001; 276(19):15609-15. DOI: 10.1074/jbc.M010573200. View

16.

Kapoor S, Triola G, Vetter I, Erlkamp M, Waldmann H, Winter R . Revealing conformational substates of lipidated N-Ras protein by pressure modulation. Proc Natl Acad Sci U S A. 2011; 109(2):460-5. PMC: 3258604. DOI: 10.1073/pnas.1110553109. View

17.

Zhou Y, Prakash P, Gorfe A, Hancock J . Ras and the Plasma Membrane: A Complicated Relationship. Cold Spring Harb Perspect Med. 2017; 8(10). PMC: 6169983. DOI: 10.1101/cshperspect.a031831. View

18.

Plowman S, Williamson D, OSullivan M, Doig J, Ritchie A, Harrison D . While K-ras is essential for mouse development, expression of the K-ras 4A splice variant is dispensable. Mol Cell Biol. 2003; 23(24):9245-50. PMC: 309700. DOI: 10.1128/MCB.23.24.9245-9250.2003. View

19.

Burd C, Liu W, Huynh M, Waqas M, Gillahan J, Clark K . Mutation-specific RAS oncogenicity explains NRAS codon 61 selection in melanoma. Cancer Discov. 2014; 4(12):1418-29. PMC: 4258185. DOI: 10.1158/2159-8290.CD-14-0729. View

20.

Koera K, Nakamura K, Nakao K, Miyoshi J, Toyoshima K, Hatta T . K-ras is essential for the development of the mouse embryo. Oncogene. 1997; 15(10):1151-9. DOI: 10.1038/sj.onc.1201284. View